The aim of the present study was to assess which factors influence hematopoietic function long term after transplantation. For this purpose, we have analyzed a series of 79 patients who underwent autologous transplantation. None of them received any further chemotherapy or radiotherapy after transplant. All patients were disease-free 1 year after autologous transplantation. Late impairment of hematopoietic function was defined as the presence of non-transient peripheral blood cytopenias, detected 6 and 12 months after autografting. Before transplantion, 38.7% of patients showed peripheral blood cytopenias. Six and 12 months after transplantation, cytopenias presented in 44.2% and 42.4% of patients, respectively. Cases displaying cytopenias 6 months after transplantation had received a significantly lower dose of CFU-GM and CD34
Autologous stem cell transplantation is increasingly used for the treatment of hematological and non-hematological disorders. [1] [2] [3] A great deal of information is now available regarding the factors which influence early hematopoietic reconstitution following stem cell transplantation. [4] [5] [6] [7] Most of these studies have focused on analysis of the role played by the inoculum and a correlation between the number of CD34 and CFU-GM per kilogram infused and engraftment observed. [8] [9] [10] [11] Other variables which affect hematopoietic
Correspondence: MC del Cañizo, Servicio de Hematologia, Hospital Universitario de Salamanca, P o de San Vicente, 58-182, 37007-Salamanca, Spain Received 3 December 1998; accepted 17 February 1999 recovery are: number of prior chemotherapeutic regimens and age 12 -both with a negative effect -and source of progenitor cells. 6, 12 Clinical studies have shown that mobilized peripheral blood (PB) stem cells as compared to bone marrow (BM) cells are associated with earlier hematological recovery and reduced usage of blood components during the post-transplant period. [13] [14] [15] [16] In contrast to early hematopoietic reconstitution, information concerning long-term engraftment is scanty. 12, 17, 18 Quality of late hematopoietic function can be influenced by the number of progenitor cells infused and the number of prior chemotherapy regimens. The aim of the present study was to assess which factors influence hematopoietic function long term after transplantation. For that purpose, we analyzed a series of 79 patients who had undergone autologous transplantation. Late impairment of hematopoietic function was defined as the presence of non-transient peripheral blood cytopenias, detected 6 and 12 months after autografting.
Patients and methods

Patients
This study was based on 79 patients at our institution who had received high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. None of them received any further chemotherapy or radiotherapy after transplant. All patients were disease-free 1 year after autologous transplantation. Patient characteristics are summarized in Table 1 . Thirty-two cases had received autologous BM cells alone, 43 PB cells alone, and four BM along with PB cells. The median doses of cyclophosphamide, melphalan, mechloretamine and procarbazine received by each patient were calculated. For evaluation of the influence of of procarbazine. These are the equivalent doses to one cycle of standard chemotherapy. The total alkylating effect was estimated from the sum of these modules.
Stem cell harvesting procedures
Bone marrow was harvested from the posterior iliac crests under general anesthesia using standard procedures. 19 Peripheral blood stem cells were mobilized after administration of G-CSF at a dosage of 5 g/kg/day subcutaneously for 4 consecutive days with leukapheresis beginning at day 5. Leukapheresis was performed, using a Fenwal CS3000 Plus cell separator (Baxter Healthcare, Deerfield, IL, USA), daily until the target cell dose of 4 ϫ 10 8 mononuclear cells (MNC) per kg was obtained. Leukocyte counts were performed with a MAXM automatic counter (Coulter Electronics, Hialeah, FL, USA). The percentage of MNC was estimated on a May-Grünwald Giemsa stained smear and then the total number of MNC per kg was calculated, multiplying the percentage of MNC by the leukocyte count and dividing the result by the patient's weight. Stem cells were frozen in 10% dimethylsulfoxide (DMSO) using controlled rate freezing, prior to storage at Ϫ196°C in liquid nitrogen.
Transplantation procedures
Patients with non-Hodgkin's lymphoma and Hodgkin's disease were conditioned with BEAM, patients with breast cancer with cyclophosphamide, carboplatin and tiotepa, myeloma multiple patients with melphalan, and patients with acute leukemia with busulfan and cyclophosphamide ± VP-16. Stem cell products were thawed at 37°C in water and infused in one or two divided doses depending on the volume. The day of infusion was designated day 0. G-CSF, 5 g/kg, was administered subcutaneously beginning at day 6 until the absolute neutrophil count was greater than 1 ϫ 10 9 /l for 3 consecutive days.
Flow cytometry and colony assays
Cells were stained using a monoclonal anti-CD34 (anti-HPCA-2) conjugated with phycoerythrin and analyzed by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA), as previously published. 20 For data acquisition the LYSIS II software program (Becton Dickinson) was used and a two-step acquisition was performed. In the first step, acquisition of all cells in the samples was performed, measuring at least 10 000 events. In a second step, a multiparametric live-gate of SSC low/CD34 ϩ cells was performed and information on at least 300 000 events was collected Analysis was performed using the PAINT-A-GATE Plus software program (Becton Dickinson).
Calibration of the instrument was performed prior to data acquisition using previously well-stablized protocols, and the CD34/CD8/CD3 positive control sample as well as bead standards.
Hematopoietic colony assays (CFU-GM) were performed as previously described, 21 using the method designed by Iscove et al. 22 Briefly, 1 ϫ 10 5 mononuclear cells/ml in Iscove's modified Dulbecco's medium (IMDM) were plated on 35 mm Petri dishes in 0.9% methylcellulose containing 10% PHA-leukocyte conditioned medium (PHA-LCM), 10% bovine serum albumin and 10% human AB serum. 23 Assays were performed in duplicate. Cultures were incubated at 37°C in a fully humidified atmosphere with 5% CO 2 and scored at day 14 under an inverted microscope.
Impaired engrafment criteria
Persistent peripheral blood cytopenia more than 6 and 12 months after transplantation was considered as impaired engraftment long term after transplant. For definition of cytopenia we considered the following values: Hb Ͻ10 g/dl, leukocyte count Ͻ4 ϫ 10 9 /l and platelet count Ͻ100 ϫ 10 9 /l.
Statistical analysis
Student's t-test, rank sum Mann-Whitney and 2 test were used to analyze the data (SPSS for Windows). Two-sided P values of 0.05 were taken as statistically significant.
Results
Before transplantion 38.7% of patients had peripheral blood cytopenias. Six and 12 months after transplantation, cytopenias were present in 44.2% and 42.4% of patients, respectively. The percentages of cases with bicytopenia and pancytopenia were 5.3% and 1.3%, respectively, before transplantation, 25.4% and 1.5% 6 months after the procedure and 16.9% and 3.4% after 12 months. Mean values of Hb, leukocytes and platelets are listed in Table 2 . Hb values increased after the procedure (P Ͻ 0.01), leukocytes remained stable while the platelet cell line was the most affected (P Ͻ 0.01). Platelet counts decreased significantly 6 months after transplant but after 12 months a recovery was observed.
The mean numbers of MNC ϫ 10 /kg infused were 5.3 ± 3.6, 43.5 ± 60 and 3.45 ± 2.4, respectively. The effect of stem cell dose on the quality of hematopoietic reconstitution is shown in Table 3 . Cases displaying cytopenias 6 months after transplantation had received a significantly lower dose of CFU-GM and CD34 ϩ cells than patients without cytopenias. The same correlation, with even higher statistical significance, was observed 12 months after transplant (Table 3) .
In order to explore whether Hb, leukocyte and platelet counts at 6 and 12 months after transplantation were influenced by the number of cells infused, we divided our patients into two groups according to the median number of MNC (5. (Table 4 and Figures 1 and 2) . The number of CFU-GM correlated sig- nificantly with Hb level at 12 months, but not at 6 months after transplantation. Interestingly, leukocyte counts were not influenced by the number of CD34 or CFU-GM cells infused. Finally, the number of MNC did not influence the peripheral blood counts long term after transplantation.
Prior alkylating therapy did not influence occurrence of long-term cytopenias. We found no differences in the amount of cyclophosphamide, melphalan, mechloretamine and procarbazine received by the patients with or without cytopenias 6 and 12 months after the procedure. Moreover, there was no difference in the total number of courses of alkylating agents received (Table 5) . Neither age nor previous radiotherapy influenced the quality of hematopoiesis, 6 and 12 months after transplantation.
Regarding diagnosis, we observed that the proportion of cases with cytopenias 6 and 12 months after transplantation 292 Data are expressed as mean Ϯ standard deviation. Statistically significant differences are printed in bold. was higher in the cohort of patients with acute leukemia (71.4% and 57.1% of cases, respectively) and breast cancer (45.5% and 45.5% of cases) than among lymphoma (35.7% and 25%) and myeloma (20% and 20%) patients, but differences did not reach statistical significance.
The incidence of cytopenias at 6 and 12 months was 43.8% and 34.% in patients who received BM progenitor cells and 30.2% and 25.6% in patients who received PB cells. These differences did not reach statistical significance.
Discussion
Over the past few years several groups have studied the factors that influence early engraftment after autologous transplantation. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, variables that influence hematopoiesis function long term after transplantation have not been analyzed sufficiently.
Our study shows that the incidence of cytopenias is similar before and after transplantation. Hematopoiesis is damaged before undertaking the transplant process and this can be attributed to the chemotherapy and radiotherapy administered before transplant. Pre-transplant, the change which predominates is a decreased Hb value, but it increases after the procedure, and at 12 months most patients have Hb levels within the normal range. It has been pointed out that thrombopoiesis is the best indicator of graft function. 6, 18 Consistent with these data, we have seen that platelets are the most affected blood parameter, with a marked decrease at 6 months after transplantation, although 12 months after the process a slight recovery in platelet number was observed.
The number of infused CFU-GM and CD34 ϩ cells appears to be the most important factor for predicting quality of engraftment. Several groups have previously shown the importance of these parameters for early hematopoietic reconstitution. 5, 6, 10, 18, 24, 25 Recently, Kiss et al 17 have shown that the dose of CD34 also influences late engraftment following autologous PB stem cell transplantation as assessed by the presence of higher PB counts in patients receiving high numbers of CD34 ϩ cells. Moreover, Bacigalupo et al 18 have reported that the number of CFU-GM also affects quality of graft function beyond day ϩ50 after allogeneic transplantation. In our study, we observed that the characteristics of the infused product affect graft quality persistently after transplantation, with patients who remain cytopenic 6 and 12 months after transplant having received a significantly lower number of CFU-GM and CD34 ϩ cells than patients without cytopenias. No significant differences in the incidence of cytopenias were observed according the source of stem cells. These data contrast with the report of Bentley et al, 12 who reported that patients who had received peripheral blood stem cells showed more engraftment failures than those who had received bone marrow and peripheral blood. However, the groups in this study were not homogeneous and the subset of patients who received both progenitors had been less heavily treated.
Regarding the influence of underlying disease, we found a higher percentage of cytopenias in patients with acute leukemia and breast cancer than with lymphoma patients. Ara-C, used in the treatment of acute leukemia, has been shown to impair hematopoietic function. 26 In patients with breast cancer, evidence of stromal damage following autologous transplantation has been described and since stromal function plays an important role in the maintenence of appropriate hematopoietic activity, stromal damage may account for the presence of cytopenias observed long term in these patients. 27 Nevertheless, due to the small number of patients included in the groups, these data should be interpreted with caution.
Treatment with alkylating agents prior to transplantation impairs subsequent hematopoietic reconstitution, 6 but we have not found a relationship between the dose of alkylating agents received and hematopoietic function long term after transplantation. Neither have we found a correlation with the use of previous radiotherapy or the age of patients, although Bentley et al 12 showed that age could influence hematolgical recovery after transplantation.
In conclusion, our data support that the numbers of CFU-GM and CD34
ϩ cells infused are the most important factors in the maintenance of adequate hematopoiesis long term after autologous transplantation.
